Andrew L Laccetti1, Sumit K Subudhi. 1. aDepartment of Cancer Medicine bDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abstract
PURPOSE OF REVIEW: Metastatic castration-resistant prostate cancer is in critical need of new and innovative treatment strategies. Since the approval of sipuleucel-T, the investigatory climate of prostate cancer immunotherapy has been rapidly evolving with promising developments in vaccine and immune checkpoint therapies. RECENT FINDINGS: Sipuleucel-T remains the first and only therapeutic cancer vaccine approved for its survival benefit in metastatic castration-resistant prostate cancer. Additional cancer vaccines are currently being evaluated, with the most promising being a peptide vaccine encoding prostate-specific antigen, known as prostate-specific antigen-TRICOM. Emerging data supports combinatorial strategies for vaccine therapy and a potential role for implementation in earlier stages of advanced disease. Immune checkpoint therapies have demonstrated limited success in prostate cancer with negative late phase trials for ipilimumab monotherapy and discouraging early phase results for programmed cell death protein 1 blockade. Novel immune-modulatory targets and rational combination strategies aim to produce more favorable results. Recent progress has been made to determine biologic predictors for response and toxicity in prostate cancer immunotherapy aiming to improve patient selection and safety. SUMMARY: Steady progress is anticipated in the field of prostate cancer immunotherapy including ongoing development of novel cancer vaccines, immune checkpoint therapies, and combinatorial strategies.
PURPOSE OF REVIEW: Metastatic castration-resistant prostate cancer is in critical need of new and innovative treatment strategies. Since the approval of sipuleucel-T, the investigatory climate of prostate cancer immunotherapy has been rapidly evolving with promising developments in vaccine and immune checkpoint therapies. RECENT FINDINGS:Sipuleucel-T remains the first and only therapeutic cancer vaccine approved for its survival benefit in metastatic castration-resistant prostate cancer. Additional cancer vaccines are currently being evaluated, with the most promising being a peptide vaccine encoding prostate-specific antigen, known as prostate-specific antigen-TRICOM. Emerging data supports combinatorial strategies for vaccine therapy and a potential role for implementation in earlier stages of advanced disease. Immune checkpoint therapies have demonstrated limited success in prostate cancer with negative late phase trials for ipilimumab monotherapy and discouraging early phase results for programmed cell death protein 1 blockade. Novel immune-modulatory targets and rational combination strategies aim to produce more favorable results. Recent progress has been made to determine biologic predictors for response and toxicity in prostate cancer immunotherapy aiming to improve patient selection and safety. SUMMARY: Steady progress is anticipated in the field of prostate cancer immunotherapy including ongoing development of novel cancer vaccines, immune checkpoint therapies, and combinatorial strategies.
Authors: M Mercader; B K Bodner; M T Moser; P S Kwon; E S Park; R G Manecke; T M Ellis; E M Wojcik; D Yang; R C Flanigan; W B Waters; W M Kast; E D Kwon Journal: Proc Natl Acad Sci U S A Date: 2001-12-04 Impact factor: 11.205
Authors: Charles G Drake; Amy D H Doody; Marianne A Mihalyo; Ching-Tai Huang; Erin Kelleher; Sowmya Ravi; Edward L Hipkiss; Dallas B Flies; Eugene P Kennedy; Meixiao Long; Patrick W McGary; Lee Coryell; William G Nelson; Drew M Pardoll; Adam J Adler Journal: Cancer Cell Date: 2005-03 Impact factor: 31.743
Authors: Richard V Parry; Jens M Chemnitz; Kenneth A Frauwirth; Anthony R Lanfranco; Inbal Braunstein; Sumire V Kobayashi; Peter S Linsley; Craig B Thompson; James L Riley Journal: Mol Cell Biol Date: 2005-11 Impact factor: 4.272
Authors: Celestia S Higano; Paul F Schellhammer; Eric J Small; Patrick A Burch; John Nemunaitis; Lianng Yuh; Nicole Provost; Mark W Frohlich Journal: Cancer Date: 2009-08-15 Impact factor: 6.860
Authors: Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg Journal: Blood Date: 2009-05-07 Impact factor: 22.113
Authors: Eric J Small; N Simon Tchekmedyian; Brian I Rini; Lawrence Fong; Israel Lowy; James P Allison Journal: Clin Cancer Res Date: 2007-03-15 Impact factor: 12.531
Authors: Tracy S P Heng; Gabrielle L Goldberg; Daniel H D Gray; Jayne S Sutherland; Ann P Chidgey; Richard L Boyd Journal: J Immunol Date: 2005-09-01 Impact factor: 5.422
Authors: Youmna Kfoury; Ninib Baryawno; Nicolas Severe; Shenglin Mei; Karin Gustafsson; Taghreed Hirz; Thomas Brouse; Elizabeth W Scadden; Anna A Igolkina; Konstantinos Kokkaliaris; Bryan D Choi; Nikolas Barkas; Mark A Randolph; John H Shin; Philip J Saylor; David T Scadden; David B Sykes; Peter V Kharchenko Journal: Cancer Cell Date: 2021-10-15 Impact factor: 31.743
Authors: Timothy E Krueger; Daniel L J Thorek; Alan K Meeker; John T Isaacs; W Nathaniel Brennen Journal: Prostate Date: 2018-11-28 Impact factor: 4.104
Authors: Mohammed G Ghonime; Uksha Saini; Michael C Kelly; Justin C Roth; Pin-Yi Wang; Chun-Yu Chen; Katherine Miller; Ilse Hernandez-Aguirre; Yeaseul Kim; Xiaokui Mo; Joseph R Stanek; Tim Cripe; Elaine Mardis; Kevin A Cassady Journal: J Immunother Cancer Date: 2021-10 Impact factor: 12.469
Authors: Neil S Forbes; Robert S Coffin; Liang Deng; Laura Evgin; Steve Fiering; Matthew Giacalone; Claudia Gravekamp; James L Gulley; Hal Gunn; Robert M Hoffman; Balveen Kaur; Ke Liu; Herbert Kim Lyerly; Ariel E Marciscano; Eddie Moradian; Sheryl Ruppel; Daniel A Saltzman; Peter J Tattersall; Steve Thorne; Richard G Vile; Halle Huihong Zhang; Shibin Zhou; Grant McFadden Journal: J Immunother Cancer Date: 2018-08-06 Impact factor: 13.751